First AI Platform for Prostate Cancer Care Approved by FDA

By Emily Menendez - Last Updated: December 8, 2022

Avenda Health’s artificial intelligence (AI)-powered prostate cancer care planning platform, iQuest, has received 510(k) clearance by the Food and Drug Administration (FDA). iQuest is the first AI-powered platform of its kind to aid in the development of personalized prostate cancer care plans.

The platform assists in the creation of prostate cancer care plans by using deep-learning algorithms and preexisting diagnostic information from patients to create a detailed map of where cancer is located within the prostate to develop personalized and precise treatments.

The current standard-of-care for prostate cancer involves treating the entire prostate, as magnetic resonance imaging technology is unable to detect the full extent of tumors and cancer growth within the prostate. Due to this full-organ treatment, nearly 50% of patients with prostate cancer end up losing their sexual or urinary function. The iQuest platform can help physicians select and plan treatment by providing a 3D visualization of a patient’s prostate cancer, enabling them to make decisions that consider the extent of the cancer as opposed to treating the entirety of the prostate to preserve quality of life while minimizing the cancer left behind.

The company is “excited about the potential to unlock precision care in prostate cancer with iQuest, as it is a key enabling technology for focal therapy to be a reality for urologists and patients,” Dr. Shyam Natarajan, co-founder and CEO of Avenda Health, said. “In order for a doctor to treat focally, they need to know where cancer is and the healthy tissue to avoid. This is vital information that iQuest now provides,” he added.

iQuest was developed based on multiple clinical studies utilizing a decade’s worth of research. The results of one study showed that physicians were able to improve the sensitivity of identifying prostate cancer tumor extent with iQuest from 37% to 97%. Treatment recommendation changed in 27% of the cases and leaned toward more localized forms of treatment.

iQuest can help guide physician intervention plans by being utilized alongside other treatment options such as focal treatments and active surveillance to create more detailed decision-making for whole-gland treatments, including radical prostatectomy and radiation therapy.